The world market for interferons was valued at US$3.8 billion in 2001 and was growing at a double-digit rate.  The launch of Pegasys, Roche's new long acting formulation of its interferon alfa Roferon is revitalizing the market for the hepatitis indication. Also the battle between Biogen's Avonex, Schering's Betaferon and Serono's Rebif is revitalizing the market for the multiple sclerosis indication.

The market landscape of the interferon market is changing rapidly with new products staking new strategic positions and old products losing market share. The market is application dependent with different indications approved in different markets. The impact of launch of interferon in a market is not as important as the impact of its approval for a main-line indication.  This makes interferons a multiple niche market accessible to small players. 

Interferons, State-of-the-Science & Strategic Opportunities, is a strategic consulting report that assesses both the technology status and the competitive landscape of the world interferons market. The report examines both the US and the European markets in detail, profiles leading products and companies and offers revenue forecasts to the year 2007.  The report assesses the market attractiveness and potential and evaluates different options for market entry.

Report Code : 0212AS3B

Report Price: US$485   Hard Copy (including shipping & handling) US$285  PDF format (delivered by email)              

Date Published: November 2002

Number of Pages: 30

Publisher: AS Insights Opportunity and Valuation Reports

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Bioportfolio_AS_Insights_Opportunity_and_Valuation_Reports__10.html#a21